product detail
FUCASO, developed by Nanjing IASO Biotechnology, is a groundbreaking CAR-T therapy specifically designed to target B-cell maturation antigen (BCMA). This therapy stands out for its unparalleled clinical efficacy and safety profile, providing a new hope for patients with relapsed or refractory multiple myeloma (r/rMM). Approved by the National Medical Products Administration (NMPA) on June 30, 2023, FUCASO has already demonstrated significant success in clinical applications.
Key Advantages of FUCASO
High Response Rates: FUCASO boasts an Overall Response Rate (ORR) of 98.9% and a Complete Response (CR) rate of 82.4%, significantly higher than other available treatments.
Durable Remission: Patients treated with FUCASO have shown a 12-month Progression-Free Survival (PFS) rate of 85.5%, indicating long-term remission and improved quality of life.
Safety Profile: With ≥3 grade Cytokine Release Syndrome (CRS) occurring in only 1% of patients and no reported cases of ≥3 grade Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), FUCASO offers a safer treatment option compared to other CAR-T therapies.
Cost-Effectiveness: FUCASO treatment costs significantly less than similar therapies available in the United States, making it a viable option for a broader range of patients.
Global Reach: IASO BIO has established a comprehensive treatment center network in China, capable of serving patients from around the world with integrated services from consultation to post-treatment care.
Clinical Success
The first patient treated with FUCASO has achieved five years of cancer-free survival, a remarkable milestone compared to the median Progression-Free Survival (PFS) of just 2.9 months with standard care. This highlights FUCASO's potential to transform the treatment landscape for multiple myeloma.
